Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

← catalyst calendar

NCT04999969 · results posted

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
126actual
Sites
34
Countries
Canada, South Korea, Spain +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2021-12-10actualWhen the study began enrolling
Primary completion2024-10-07actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-11-30estimatedThe whole study's end, after follow-up
First posted2021-08-11actualWhen this record first appeared on the registry
Results posted2025-11-26actualWhen the sponsor posted results to the registry
Record updated2026-08-19actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Locally Advanced or Metastatic Solid Tumours

Interventions

  • Drug: AZD0171 — also filed as MSC-1
  • Drug: Durvalumab — also filed as MEDI4736
  • Drug: Gemcitabine
  • Drug: Nab-paclitaxel

Primary outcomes

what the primary-completion date above is the date OF
Number of Participants With Adverse Events (AEs), Immune Mediated AEs (imAEs) and Serious AEs (SAEs)
measured From Cycle 1 Day 1 (each cycle was 28 days in length) until Day 90 (post last dose of study intervention), up to 34 months
Overall Survival at 12 Months (OS-12)
measured At 12 months

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2024-05-03 · 3.7 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-09-26 · 2.6 MB · SAP_001.pdf

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed